SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Paul Robeson

PatientPaul Robeson
Date of birth1967-04-09
IdentifiersMRN HR-ML048-SYN; SSN (made up) 000-48-2647
Document date2026-06-08
AuthorTheodore Bankole-Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review of depression treatment. [S]

History of Present Illness

Mr. Robeson returns three months after starting treatment. He has taken sertraline 200 mg each morning for five weeks, after two weeks at 150 mg, without missing doses and with only mild loose stools. He has attended every weekly behavioral activation session; the psychologist reports PHQ-9 scores in the high teens at each session, with no positive item 9. He walks most days but still has little pleasure, wakes at four, and has not sung or accepted any invitations. He has had no thoughts of suicide. He has had no elation or reduced need for sleep. [S]

ElementDetail
MedicinesSertraline 200 mg for five weeks after two weeks at 150 mg
TherapyEleven behavioral activation sessions
MoodPHQ-9 17 from 22
SafetyNo thoughts of suicide

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; appetite back; weight 100.2 kg
PsychiatricPositiveLittle pleasure, early waking, low drive; no thoughts of suicide; no elation
GastrointestinalPositiveMild loose stools on 200 mg
CardiovascularNegativeNo palpitations

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg tablet, one tablet each morning50 mg each morning for two weeksOral route2026-03-12 to 2026-03-25completedS
Sertraline 100 mg tablet, one tablet each morning100 mg each morningOral route2026-03-26 to 2026-04-19completedS
Sertraline 50 mg tablets, three tablets (150 mg) each morning150 mg each morning for two weeksOral route2026-04-20 to 2026-05-03completedS
Sertraline 100 mg tablets, two tablets (200 mg) each morning200 mg each morningOral route2026-05-04 to 2026-06-07completedS
Sertraline 100 mg tablet, one tablet each morning for one week, then stop100 mg each morning for one week during the switchOral route2026-06-08 to 2026-06-14completedS
Venlafaxine extended-release 75 mg capsule, one capsule each morning with food75 mg each morning for one weekOral route2026-06-08 to 2026-06-14completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-08Body height190cmS
2026-06-08Body weight100.2kgS
2026-06-08Body mass index (BMI) [Ratio]27.8kg/m2S
2026-06-08Systolic blood pressure128mm[Hg]S
2026-06-08Diastolic blood pressure80mm[Hg]S
2026-06-08Heart rate74/minS
2026-06-08Respiratory rate14/minS
2026-06-08Body temperature36.6CelS
2026-06-08Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-08Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-06-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]17{score}S

Physical Exam

Vital signs recorded on 2026-06-08; see the Vital Signs section. [S]

SystemFinding
GeneralWeight 100.2 kg; blood pressure 128/80, pulse 74
PsychiatricSlowed; affect constricted; logical; no thoughts of suicide

Problems

ProblemClinical statusVerificationCodeProvenance
About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arrangedresolvedconfirmed R53.83S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D).
Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview)activeconfirmed F33.2S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted.
Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusionactiveconfirmed Z60.5S — Synthetic coding of his documented persecution as a social determinant of his depression.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline and at least monthly during acute treatment (CMID)Completed today17, down 23 percent from 22; item 9 scored 0
SurveyPHQ-9 between visits, rated by the psychologist at each sessionAt each therapy sessionCompleted todayRated at each session since the last visit; no positive item 9 reported
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis LifelineEvery visit during active treatmentCompleted todayNo thoughts of suicide; medicines locked; safety plan reviewed
LaboratorySodium (SSRI or SNRI in an older adult)Baseline, about four to six weeks after starting, and with symptomsCompleted today137 mmol/L, normal
Medication safetyAdequacy of the antidepressant trial (dose and duration)At each review: at least four to eight weeks at an adequate dose before judging responseCompleted todayAdequate trial: five weeks at 200 mg; no response; switch to venlafaxine
Medication safetyAdherence and adverse-effect reviewEvery visitCompleted todayEvery dose taken; mild loose stools
Medication safetySwitch safety: serotonin syndrome and discontinuation symptomsDuring a cross-taperCompleted todayWarning signs explained; sertraline tapered over one week
Medication safetyBlood pressure (venlafaxine)Baseline and at every visit on venlafaxineCompleted todayBaseline 128/80 before venlafaxine
Medication safetyOverdose risk and supplyWith each prescriptionCompleted today30-day supplies; locked box
Medication safetyWatch for hypomania or mixed features after starting or changing an antidepressantEvery visit; repeat the MDQ if features emergeCompleted todayNo signs of hypomania
ReferralBehavioral activation with a psychologistWeekly for about sixteen sessionsCompleted todayEleven sessions; activity schedule continuing
Medication safetyECT indicationsAt each review of a severe episodeNot indicatedNo psychosis, refusal of food or drink, or acute suicidal risk; revisit if a second trial fails
ReferralSocial work for income and costsMonthlyCompleted todayMonthly meetings continue

Goal progress:

Guideline basis: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse phone check at one week of the switch. Review at about eleven weeks on venlafaxine with the PHQ-9, sodium and blood pressure. Weekly behavioral activation. Call or text 988 at any time in a crisis. Next scheduled visit 2026-08-24: twenty-four-week review: partial response to venlafaxine; treatment-resistant depression; aripiprazole augmentation and an informed consent discussion about ECT. [S]